Updated:
Multiple Sclerosis Society
Founded in 1946, the MS Society is the UK's largest charitable funder of multiple sclerosis research, operating from offices in London and maintaining offices...
Multiple Sclerosis Society
Founded in 1946, the MS Society is the UK's largest charitable funder of multiple sclerosis research, operating from offices in London and maintaining offices in all four UK nations. Its mission emerged from the advocacy of Sir Richard Cave and Mary Cave, whose daughter had MS, and Sylvia Lawrie, who placed an urgent newspaper advertisement in The Times soliciting for a society to pursue a cure. The charity now mobilises an annual research spend of roughly £15 million, directed by a Scientific Strategy Committee chaired by external academic experts. Direct grants and Strategic Awards underpin the Society's deployment model: basic-science discovery, translational development, and clinical trial networks. It has established the UK MS Register, tracking more than 20,000 patients, and the MS Society Tissue Bank at Imperial College London, which supplies samples to investigators worldwide. In collaboration with the Wellcome Trust, it launched the MS Clinical Trials Network in 2015, accelerating recruitment across 18 UK sites for phase II and III studies, including the Octopus trial — a multi-arm, multi-stage platform trial testing repurposed drugs such as metformin and alpha-lipoic acid against progressive MS. The Society also operates a fellowship scheme that has trained roughly 300 early-career researchers and PhD students. The Society manages assets across a restricted endowment and liquid reserves, with total net assets reported at £83 million in its 2023 annual report. The Conrad N. Hilton Foundation has contributed more than $71 million to the MS Society and its international federation partners, including a $27 million gift from Barron Hilton to support the Progressive MS Alliance. In September 2024, the charity announced the appointment of Ali Hutchinson as its first Director of Partnerships and Philanthropy, signaling a strategic push to diversify high-net-worth donor engagement beyond legacy fundraising. Its collaboration with corporate partners such as Biogen and Sanofi adds roughly £8 million annually in event sponsorship and research co-funding. The Society's structural differentiator lies in its dual identity as grantmaking foundation and clinical trials sponsor. It directly commissions and part-owns the trials it funds, retaining rights to key datasets and biomarkers — a posture more common in a biotech venture studio than an endowed charity. This model allowed it to co-invest in the Cambridge-based start-up LoQus23 Therapeutics, a DNA repair biotech advancing a Huntington's-inspired approach to MS neuroprotection.
General information
Firm type
Endowment / Foundation
Year founded
1946
AUM
£100M – £300M (Altss estimate)
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Principals
Nick Moberly
Chief Executive
Sector focus
Frequently asked questions
Who runs the MS Society's research priorities?
A Scientific Strategy Committee of external neuroscientists, neurologists, and patient representatives sets the research agenda, chaired independently of the Society's executive team. The CEO, Nick Moberly, oversees operations, but grant decisions are made via peer review panels that exclude staff voting. This separation is intended to insulate scientific allocation from fundraising pressures.
How does the MS Society fund clinical trials?
The Society acts as co-sponsor or direct funder of phase II and III trials rather than a traditional grantmaking body writing blind cheques. For the Octopus platform trial, it contributed roughly £8 million and co-designed the protocol with University College London, retaining a seat on the trial steering committee and access to interim data. Its Clinical Trials Network, launched in 2015 with the Wellcome Trust, provides recruitment infrastructure across 18 UK sites.
Is the MS Society a single national entity or part of a federation?
The organisation is a single UK charity (registered no. 1139257 / SC041990) but is a founding member of the Multiple Sclerosis International Federation and the International Progressive MS Alliance. These umbrella bodies coordinate global research funding and advocacy, with the Society providing roughly 30 percent of the Progressive MS Alliance's budget. Each national MS society remains legally independent.
What proportion of the Society's income goes to research versus administration?
In the 2023 financial year, approximately 45 percent of total charitable expenditure was directed to research and clinical trials, with the remainder supporting information services, local support groups, and fundraising. The fundraised-income-to-overhead ratio hovers near 78 percent, within the top quartile of UK medical research charities per the Charity Commission's public dataset.
Does the MS Society invest its endowment directly in biotechnology companies?
The Society maintains a traditional investment portfolio rather than a proprietary venture arm, but it has strategic co-investment relationships. In 2019, it backed LoQus23 Therapeutics alongside Cambridge Enterprise and a pharma partner, funding a DNA repair target study in an approach closer to venture philanthropy than equity venture capital.
Which sectors does the MS Society explicitly avoid funding?
The Society does not fund stem-cell tourism or unregulated cell-therapy clinics, and it has a formal policy against supporting animal-testing alternatives that lack validated academic methodology — a stance publicly challenged by some patient advocacy groups in 2022. It also does not fund for-profit care-home operators or pharmaceutical company marketing activities.
How is the Progressive MS Alliance structured relative to the MS Society?
The Alliance pools funding from the UK MS Society, the US National MS Society, MS Canada, and the Italian MS Society. The UK chapter houses the Alliance's executive secretariat and chairs its steering committee. Since 2014, the Alliance has deployed over $75 million into research specifically targeting progressive MS, a form historically neglected by industry because of smaller drug-market projections.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: